FIELD: biochemistry.
SUBSTANCE: invention relates to an anti-CD19 antibody or antigen-binding fragment thereof, as well as to a conjugate, a chimeric antigen receptor and a pharmaceutical composition containing said antibody or fragment thereof. Also disclosed is a nucleic acid encoding said antibody, a nucleic acid encoding said chimeric antigen receptor, as well as a cell containing said nucleic acid. Invention also relates to a method of treating a disease or disorder in which CD19 is expressed.
EFFECT: invention enables effective treatment of a disease or disorder in which CD19 is expressed.
44 cl, 18 dwg, 9 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTI-IDIOTYPIC ANTIBODIES AND METHODS RELATED TO THEM | 2017 |
|
RU2773355C2 |
| LABELED CHIMERIC EFFECTOR MOLECULES AND RECEPTORS THEREOF | 2014 |
|
RU2729463C2 |
| CANCER TREATMENT WITH CHIMERIC CD33 ANTIGEN RECEPTOR | 2015 |
|
RU2747384C2 |
| TREATING CANCER BY HUMANISED ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR | 2014 |
|
RU2711975C2 |
| REAGENTS FOR REPRODUCTION OF CELLS EXPRESSING RECOMBINANT RECEPTORS | 2018 |
|
RU2783956C2 |
| ANTIBODY AGENTS SPECIFIC TO HUMAN CD19, AND THEIR APPLICATIONS | 2016 |
|
RU2773317C2 |
| CELL | 2015 |
|
RU2768019C2 |
| METHOD AND COMPOSITIONS FOR CELL IMMUNOTHERAPY | 2013 |
|
RU2700765C2 |
| HIV ANTIBODY COMPOSITIONS AND METHODS FOR THEIR APPLICATION | 2016 |
|
RU2757135C2 |
| CHIMERIC ANTIGEN RECEPTORS FOR BCMA AND THEIR USE | 2019 |
|
RU2785658C2 |
